In addition, IL-8 levels were more prominent in OA treatment than EGF treatment, suggesting that IL-8 can be a diagnostic or prognostic marker for predicting metastasis in CRC harboring KRAS/p53 mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.